Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28272985 | 0.90 | KDM1A (0.41) | KDM1AMAOBHDAC8HDAC6MAOA | |
| SCHEMBL21775670 | 0.83 | KDM1A (0.41) | KDM1AMAOBSLC6A3SLC6A4HDAC8 | |
| SCHEMBL18817746 | 0.83 | KDM1A (0.41) | KDM1AMAOBSLC6A3SLC6A4HDAC8 | |
| SCHEMBL21784349 | 0.83 | KDM1A (0.41) | KDM1AMAOBSLC6A3SLC6A4HDAC8 | |
| SCHEMBL18817744 | 0.83 | KDM1A (0.41) | KDM1AMAOBSLC6A3SLC6A4HDAC8 | |
| SCHEMBL23867768 | 0.83 | KDM1A (0.41) | KDM1AMAOBSLC6A3SLC6A4HDAC8 | |
| SCHEMBL19091464 | 0.83 | KDM1A (0.41) | KDM1AMAOBSLC6A3SLC6A4HDAC8 | |
| SCHEMBL20134529 | 0.82 | SLC6A2 (0.42) | KDM1AMAOBSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL22465807 | 0.81 | SLC6A3 (0.40) | KDM1AMAOBSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL19609139 | 0.81 | SLC6A3 (0.40) | KDM1AMAOBSLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220281815-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2022-09-08 | — | — | US | disclosed |
| US-11352322-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200308110-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2020-10-01 | — | — | US | disclosed |
| WO-2017195216-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308110-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | KDM1A 13/4885MAOB 58/4885SLC6A3 280/4885 |
| US-11352322-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | KDM1A 13/4885MAOB 58/4885SLC6A3 280/4885 |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | KDM1A 15/4885MAOB 45/4885SLC6A3 168/4885 |
| US-20220281815-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | KDM1A 15/4885MAOB 45/4885SLC6A3 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.